Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals

Docket No.
1:21-cv-00691
District Court
Delaware

Goal

  • Block infringement of a patent

Litigation Content

Why this Matters:

The plaintiffs argue that defendants infringed several of their patents, and defendants counter that plaintiffs improperly listed their patents in the Orange Book to maintain exclusivity and block other generics from entering the market in violation of federal patent and antitrust law. Patent abuses can distort the market for prescription drugs and drive up prices for consumers.

 

Potential Impact:

Improper patent listings in the Orange Book can undermine fair competition and prohibit or delay consumers from accessing lower-cost generic drugs.

 

142 Major Filings

View More

Litigation Information

Current Status

CASE DISMISSED